



9th EBF Young Scientist Symposium

It's the New Dawn Defining our (Bioanalytical) Future Together

10-12 May 2023

The Radisson Blu - Hasselt - Belgium

Day 0: Wednesday 10 May 2023

- 12:00** **Registration desk opens**
- 13:00** **19:00** **EBF University - included in the conference registration**
Program is being developed
The training will focus on understanding the drug development process for NCEs and NBEs, i.e. which studies are programmed when and why in the development process, which decisions are taken by these studies and how can bioanalysis play an optimal role in supporting the projects.
Experts from the project teams will be invited to provide the training.
- 19:00** **Free Evening in Hasselt**

Day 1: Thursday 11 May 2023

- 08:00** **Registration desk opens**
- 08:45** **09:00** **Welcome and introduction to the 9th YSS**
Philip Timmerman, EBF
- 09:00** **10:00** **(Plenary) Session 1: Can Automation Deliver on Promise?**
Session chairs: assignment ongoing
- 09:00** **09:20** Rosie Penford, GSK
The Evolution of Automation for Ligand Binding Assays
- 09:20** **09:40** Paul Heads, Orion Corporation
Does automating a bioanalytical laboratory have to cost excessive amounts of time and money?
- 09:40** **10:00** Ewa Cendrowicz, ICON plc
Automated PBMC isolations – gain in time, number of cells and quality of samples
- 10:00** **10:30** **Coffee break**
- 10:30** **11:50** **(Plenary) Session 2: New Tech Entering the BA Toolbox**
Session chairs: assignment ongoing
- 10:30** **10:50** Kyriel M. Pineault, UCB Pharma
Qualification of a duplex ddPCR assay to support biodistribution and shedding assessment of a Gene Therapy product
- 10:50** **11:10** Jakob Alhede, AstraZeneca
Challenges in the application of Branched DNA as a bioanalytical tool for the quantification of RNA therapeutics
- 11:10** **11:30** Zoe Georgakopoulou, Drug Development Solutions (DDS)
Streamlining Flow cytometry
- 11:30** **11:50** Victoria Wingfield, Drug Development Solutions (DDS)
Controlling the Flow

11:50 12:00 **Introduction to the Science Café**

12:00 13:00 **Lunch - tables grouped to start Science Café discussions**

13:00 15:30 **9th Science Cafe (Format: round table): The Right Balance**

Ever since the 4th YSS, a "Science Café" is part of the YSS program. Also this year, we want to include a SC in which we focus on a specific aspect of (y)our community responsibility.

After 3 years of struggle with Covid in a changing world, the 9th YSS SC plans to focus on a theme which is an important challenge: finding the right balance, e.g. work-life balance, technology being an opportunity to refocus, regulations being a challenge or a partner. In short, identifying a SWOT to manage pressure and helping the next generation to grow in responsibility and aspirations. We don't have all the details ironed out, but a survey is being prepared as a stepstone for our discussions.

15:30 16:00 **Coffee break**

16:00 17:40 **(Parallel) Session: Troubleshooting LCMS**

Session chairs: assignment ongoing

16:00 16:20 Katie Webb, Labcorp Drug Development

The unwanted guest in your chromatography separation

16:20 16:40 Isabel Stiltz, Nuvisan

Combined LC-MS/MS method for a highly instable small molecule and its two metabolites – complication and troubleshooting

16:40 17:00 Sophie Roos, Byondis

Challenges in the development of an LC-MS method for quantitation of sMET in human plasma

17:00 17:20 Daniel Alejandro Diaz Checa, NovoNordisk

Increasing robustness and column lifetime in LC MS/MS analysis of plasma samples - part 1

17:20 17:40 Xavier Nuno Martinez Galanes, NovoNordisk

Increasing robustness and column lifetime in LC MS/MS analysis of plasma samples - part 2

16:00 17:40 **(Parallel) Session: Troubleshooting LBA**

Session chairs: assignment ongoing

16:00 16:20 Hannah Vernon-Browne, Drug Development Solutions (DDS)

Bridging immunoassay kits in the biomarker field: Two Case Studies

16:20 16:40 Francesca Minelli, Merck KGaA

Soluble target quantification: challenges in method development

16:40 17:00 Fabian Gärtner, Nuvisan

Avoid the Hook Effect in homogenous MSD assays (Don't get hooked on homogenous assays)

17:00 17:20 Sanam Ahmad, GSK

Troubleshooting analyte carryover on the Gyrolab Platform

17:20 17:40 Ian de Bus, Sanquin Diagnostic Services

Haemostatic biomarkers; how to correctly analyse them in a quantitative manner?

19:30 22:00 **9th EBF YSS Conference dinner (included in registration)**

Day 2: Friday 12 May 2023

09:00 09:15 **Feedback from the Science Café**

09:15 10:10 **(Plenary) Session: Can we do Less and Achieve More?**

Session chairs: assignment ongoing

09:15 09:35 Amber Bennett, Synexa Life Sciences

Correlation of screening and titre results to reduce analysis costs and increase delivery of patient immunogenicity data

09:35 09:55 Leroy Schreuder, ICON plc

Singlicate analysis applied to pharmacokinetic ligand binding assays: an overview of benefits and limitations.

09:55 10:10 Cathy M. Jacobs, U. Saarbrücken

Development of an LC-HRMS-based approach for adherence monitoring of breast cancer medication in four different matrices

10:10 10:30 *Panel discussion: Reducing Cost.*

10:30 10:50 Poster Pitches

3-5 min poster presentations for submitted posters signing up for this session
deadline for submission = 31st March 2023 via <https://yss.e-b-f.eu/submit-an-abstract/>

10:50 11:20 Discussions @ posters during coffee break

11:20 12:40 (Parallel) Session: Getting More out of our Toolbox A

Session chairs: assignment ongoing

11:20 11:40 Desislava Galeva, Labcorp Drug Development

An alternative approach to the classic anti-drug antibody (ADA) titer assay used in a clinical trial

11:40 12:00 Sabrina Zadic, Swiss BioQuant

How to adapt and ADA method to a vaccine efficacy study

12:00 12:20 Syed Raza ul Haq, AstraZeneca

Development of Ligand Binding Assay for PK measurement of mouse surrogates of human therapeutic antibodies in mouse plasma and tissues.

12:20 12:40 panel discussion

11:20 12:40 (Parallel) Session: Getting More out of our Toolbox B

Session chairs: assignment ongoing

11:20 11:40 Fiona Flett, Charles River Laboratories

Glycobiology Growth in the Bioanalytical space: The Development of an LC-MS Assay for Quantitation of Glycosaminoglycans

11:40 12:00 Marie Reille-Seroussi, Sanofi

Quantification of next generation biotherapeutics: Recent case studies for which LC-MS showed clear advantages over LBA.

12:00 12:20 Patrick Schreier, Abbvie

Determination of soluble RGMa in human Serum and CSF using LC-MS/MS

12:20 12:40 Grigori Singovski, F. Hoffmann - La Roche

title to be confirmed

12:40 13:40 Lunch break

13:40 15:00 (Parallel) Session: Being Tolerant...

Session chairs: assignment ongoing

13:40 14:00 Lianne Dijk, Sanquin Diagnostic Services

Development of a novel drug-tolerant ADA assay: the acid-dissociation lanthanide-fluorescence immunoassay (ALFIA)

14:00 14:20 Kenzie Granger, Labcorp Drug Development

Evaluation of multiple ADA assay formats for achieving drug tolerance

14:20 14:40 Jayshree Maher, AstraZeneca

The technical challenges of developing target tolerant immunogenicity assays

14:40 15:00 Giorgia Rota

The Challenges of developing functional cell-based neutralizing antibody assays

13:40 15:00 (Parallel) Session: Optimising New Tools in Support of Patient Comfort

Session chairs:

13:40 14:00 Laura Boffel, U Ghent

In-depth evaluation of automated non-contact reflectance-based hematocrit prediction of dried blood spots

14:00 14:20 presenter confirmed

awaiting abstract approval

14:20 14:40 Liesl Heughebaert, U Ghent

Application of non-contact hematocrit prediction technologies to overcome hematocrit effects on immunosuppressant quantification from dried blood spots

14:40 15:00 Hanna De Baets, U Ghent

Capillary application of (volumetric) dried blood spot assays for tacrolimus and creatinine determination in stem cell transplant patients: preliminary results.

15:00 15:30 **Coffee Break**

15:30 16:30 **(Parallel) Session:: When Using Multiple Assays A**

Session chairs: assignment ongoing

15:30 15:50 Aleksandra Seydel, Novartis AG

Transfer of in-licensed BA Assays for Large Molecule: an uphill Climb to Success

15:50 16:10 Nicholas Butler, F-star Therapeutics

A direct assay comparison between the V-PLEX and S-PLEX proinflammatory panel 1 – Does improved sensitivity equal improved assay?

16:10 16:30 Katja Zeiser, Nuvisan

The somewhat different clinical study: from first thoughts to the final assay setup

15:30 16:30 **(Parallel) Session:: When Using Multiple Assays B**

Session chairs: assignment ongoing

15:30 15:50 Brian Dan, F. Hoffmann - La Roche

title to be confirmed

15:50 16:10 presenter confirmed

awaiting abstract approval

16:10 16:30 panel discussion: method transfer and cross validation

16:30 16:45 **Closing Remarks and Announcement 2023 YSS Best Poster Winner**

16:45 **Adjourn**

Meeting Organisation:

Eva Hanckmann, Byondis; Liesl Heughebaert, Ghent University; Elien Van Nuffel, Sanofi; Cathy Jacobs, Saarland University; Kate Groves, UCB Pharma (until 15JAN2023), Kyriel Pineault, UCB Pharma (From 16JAN2023); Lisa Wolter, Abbvie; Paul Heads, Orion Corporation; Sabrina Zadic, Swiss Bioquant; Katja Zeiser, Nuvisan; Claire Szuster, DDS; Manca Spental, NovoNordisk; Amelia Roberts, Quotient Sciences; Harriet Thomas, GSK; Bodrul Noor, AstraZeneca; Mariana Carneiro Da Cunha, Intertek; Joury van 't Klooster, ICON plc ; Marie Reille-Seroussi, Sanofi; Francesca Minelli, Merck KGaA; Brian Dan, F. Hoffmann La Roche; James Beecroft, F. Hoffmann La Roche; Lisa Seavers, Labcorp Drug Development; Juel Maalouli Schaar, Saarland University; Giusy Tespio, Unibo (until 31JAN2023); Lorenzo Marincich, Unibo (From 01FEB2023) and Dean Hogan, Charles River Laboratories.

Meeting Management: Philip Timmerman (EBF)

Patrons of the 9th YSS: <https://yss.e-b-f.eu/yss-patronage/>

The symposium is organised as a non-profit event by the EBF vzw. The organisation of the conference is independent of all EBF member companies.
